Inventors:
- Weisbaden, DE
Michael Roguska - Ashland MA, US
Michael Paskind - Sterling MA, US
Subhashis Banerjee - Shrewsbury MA, US
Daniel Edward Tracey - Hamilton, BM
Michael White - Framingham MA, US
Zehra Kaymakcalan - Westborough MA, US
Boris Labkovsky - Marlborough MA, US
Paul Sakorafas - Newton Highlands MA, US
Geertruida M. Veldman - Sudbury MA, US
Amy Venturini - Lexington MA, US
Angela Widom - Acton MA, US
Stuart Friedrich - Cary, CA
Nicholas W. Warner - Andover MA, US
Angela Myles - Pepperell MA, US
John Gawain Elvin - Royston, GB
Alexander Robert Duncan - Cambridge, GB
Elaine Joy Derbyshire - Berks, GB
Sara Carmen - Cambridge, GB
Stephen Smith - Ely, GB
Thor Las Holtet - Ronde, DK
Sarah Du Fou - Hitchen, GB
International Classification:
C07K 16/24
A61K 9/00
A61K 45/06
A61K 39/395
US Classification:
424 852, 4241581, 4241451, 424 851
Abstract:
Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.
